P616: Utility of zinc protoporphyrin/haem ratio as a marker of iron deficiency with or without anaemia in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P617: Single-centre experience with biological treatment in budesonide-refractory microscopic colitis patientsECCO '18 Vienna
2018
P618: Post-operative pain following laparoscopic right hemicolectomy for Crohn’s disease a comparative studyECCO '18 Vienna
2018
P619: Systematic review: Psychosocial factors associated with pain in inflammatory bowel diseaseECCO '18 Vienna
2018
P621: Faecal calprotectin after the induction of anti-TNF therapy predicts mucosal healing in patients with ulcerative colitis: A prospective single-centre studyECCO '18 Vienna
2018
P623: Quality of life as predictor of biological levels decay in inflammatory bowel diseasesECCO '18 Vienna
2018
P624: Vedolizumab can induce clinical remission in patients with chronic antibiotic-refractory pouchitis: A retrospective single-centre experienceECCO '18 Vienna
2018
P625: A prospective study to assess the effectiveness of tacrolimus therapy in ulcerative colitisECCO '18 Vienna
2018
P626: Development of a model of 3D imaging for the pre-operative planning of TaTMEECCO '18 Vienna
2018
P628: Transfer of care of adolescent IBD patients without longitudinal transition: Lesson from 10-year experiencesECCO '18 Vienna
2018
P629: Impact of surgical treatment on quality of life in Crohn’s disease: Short-and longer-term follow-upECCO '18 Vienna
2018
P630: Development and evaluation of BioCLIA-Tracker infliximab kit: A fast and innovative chemiluminescent assay for the monitoring of patients treated with infliximabECCO '18 Vienna
2018
P631: Treatment of established post-operative recurrence of Crohn’s disease with anti-TNF agents: Preliminary data of a multicentre, nationwide studyECCO '18 Vienna
2018
P632: Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitisECCO '18 Vienna
2018